Management strategies in heart failure with preserved ejection fraction View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-05-06

AUTHORS

Jan Wintrich, Amr Abdin, Michael Böhm

ABSTRACT

The diagnosis and therapy of heart failure with preserved ejection fraction (HFpEF) remain challenging. Currently, there are ongoing discussions on whether the diagnosis of HFpEF should be based solely on left ventricular ejection fraction, which may not account for the heterogeneity of HFpEF syndrome. This aspect has been addressed by the recently proposed HFA-PEFF and the H2FPEF algorithms, which take numerous diagnostic modalities into account to establish the diagnosis of HFpEF. Moreover, this review focuses on the adequate treatment of comorbidities and risk factors in HFpEF that should be an essential part of any HFpEF therapy. Furthermore, the management of fluid level in HFpEF patients is pointed out, as it plays an important role in symptom control. In addition, the value of LCZ696 therapy in HFpEF is discussed. Although LCZ696 had neutral effects in the large PARAGON-HF trial, it had previously been granted an extended indication by the Food and Drug Administration. Since the publication of the EMPEROR-Preserved trial, empagliflozin now represents the first drug to significantly improve the prognosis of HFpEF patients. Therefore, the role of SGLT2 inhibitors in HFpEF management is highlighted. Overall, this review aims to enhance the knowledge on the diagnostic processes and best treatments available for HFpEF patients. More... »

PAGES

332-339

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-022-05119-5

DOI

http://dx.doi.org/10.1007/s00059-022-05119-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147680082

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35524007


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transporter 2 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke Volume", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ventricular Function, Left", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wintrich", 
        "givenName": "Jan", 
        "id": "sg:person.07362710151.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07362710151.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abdin", 
        "givenName": "Amr", 
        "id": "sg:person.01075440347.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075440347.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "B\u00f6hm", 
        "givenName": "Michael", 
        "id": "sg:person.01252023603.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252023603.69"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrcardio.2017.65", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085388588", 
          "https://doi.org/10.1038/nrcardio.2017.65"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-019-01411-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112260110", 
          "https://doi.org/10.1007/s00392-019-01411-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11897-014-0219-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006262431", 
          "https://doi.org/10.1007/s11897-014-0219-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-019-01477-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1113380525", 
          "https://doi.org/10.1007/s00392-019-01477-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-020-01633-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1126009394", 
          "https://doi.org/10.1007/s00392-020-01633-w"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-018-1344-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105856283", 
          "https://doi.org/10.1007/s00392-018-1344-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-018-1302-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105178358", 
          "https://doi.org/10.1007/s00392-018-1302-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-017-1170-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092151548", 
          "https://doi.org/10.1007/s00392-017-1170-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-018-1210-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100823936", 
          "https://doi.org/10.1007/s00392-018-1210-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-06", 
    "datePublishedReg": "2022-05-06", 
    "description": "The diagnosis and therapy of heart failure with preserved ejection fraction (HFpEF) remain challenging. Currently, there are ongoing discussions on whether the diagnosis of HFpEF should be based solely on left ventricular ejection fraction, which may not account for the heterogeneity of HFpEF syndrome. This aspect has been addressed by the recently proposed HFA-PEFF and the H2FPEF algorithms, which take numerous diagnostic modalities into account to establish the diagnosis of HFpEF. Moreover, this review focuses on the adequate treatment of comorbidities and risk factors in HFpEF that should be an essential part of any HFpEF therapy. Furthermore, the management of fluid level in HFpEF patients is pointed out, as it plays an important role in symptom control. In addition, the value of LCZ696 therapy in HFpEF is discussed. Although LCZ696 had neutral effects in the large PARAGON-HF trial, it had previously been granted an extended indication by the Food and Drug Administration. Since the publication of the EMPEROR-Preserved trial, empagliflozin now represents the first drug to significantly improve the prognosis of HFpEF patients. Therefore, the role of SGLT2 inhibitors in HFpEF management is highlighted. Overall, this review aims to enhance the knowledge on the diagnostic processes and best treatments available for HFpEF patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-022-05119-5", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "diagnosis of HFpEF", 
      "HFpEF patients", 
      "ejection fraction", 
      "heart failure", 
      "left ventricular ejection fraction", 
      "numerous diagnostic modalities", 
      "EMPEROR-Preserved trial", 
      "ventricular ejection fraction", 
      "PARAGON-HF trial", 
      "HFA-PEFF", 
      "HFpEF therapy", 
      "LCZ696 therapy", 
      "HFpEF management", 
      "symptom control", 
      "SGLT2 inhibitors", 
      "HFpEF syndrome", 
      "risk factors", 
      "extended indications", 
      "first drug", 
      "diagnostic modalities", 
      "HFpEF", 
      "adequate treatment", 
      "Drug Administration", 
      "fluid levels", 
      "patients", 
      "therapy", 
      "best treatment", 
      "diagnosis", 
      "diagnostic process", 
      "trials", 
      "neutral effect", 
      "treatment", 
      "H2FPEF", 
      "comorbidities", 
      "LCZ696", 
      "failure", 
      "review", 
      "prognosis", 
      "syndrome", 
      "administration", 
      "important role", 
      "drugs", 
      "management", 
      "modalities", 
      "inhibitors", 
      "role", 
      "management strategies", 
      "indications", 
      "food", 
      "fraction", 
      "factors", 
      "levels", 
      "control", 
      "ongoing discussion", 
      "effect", 
      "heterogeneity", 
      "essential part", 
      "addition", 
      "publications", 
      "strategies", 
      "knowledge", 
      "aspects", 
      "part", 
      "values", 
      "discussion", 
      "process", 
      "account"
    ], 
    "name": "Management strategies in heart failure with preserved ejection fraction", 
    "pagination": "332-339", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147680082"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-022-05119-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35524007"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-022-05119-5", 
      "https://app.dimensions.ai/details/publication/pub.1147680082"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_939.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-022-05119-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05119-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05119-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05119-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05119-5'


 

This table displays all metadata directly associated to this object as RDF triples.

202 TRIPLES      21 PREDICATES      107 URIs      90 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-022-05119-5 schema:about N159b7d539a0047fba4ef6526dab62ec5
2 N28b81c3f53ad4f148b4660b7dfc45e05
3 N56338cdac5c146768cb499985c284f80
4 N7b39c66b9f1e4fc697e691a3f833b15e
5 Ncb3e480db10f4597b5de18c42466a7cc
6 Ndd5e8242d2f0444c8cc52ee2c50ced77
7 anzsrc-for:11
8 anzsrc-for:1102
9 schema:author Nf73ddae420aa49d3a933c2e6959de4c9
10 schema:citation sg:pub.10.1007/s00392-017-1170-6
11 sg:pub.10.1007/s00392-018-1210-x
12 sg:pub.10.1007/s00392-018-1302-7
13 sg:pub.10.1007/s00392-018-1344-x
14 sg:pub.10.1007/s00392-019-01411-3
15 sg:pub.10.1007/s00392-019-01477-z
16 sg:pub.10.1007/s00392-020-01633-w
17 sg:pub.10.1007/s11897-014-0219-3
18 sg:pub.10.1038/nrcardio.2017.65
19 schema:datePublished 2022-05-06
20 schema:datePublishedReg 2022-05-06
21 schema:description The diagnosis and therapy of heart failure with preserved ejection fraction (HFpEF) remain challenging. Currently, there are ongoing discussions on whether the diagnosis of HFpEF should be based solely on left ventricular ejection fraction, which may not account for the heterogeneity of HFpEF syndrome. This aspect has been addressed by the recently proposed HFA-PEFF and the H2FPEF algorithms, which take numerous diagnostic modalities into account to establish the diagnosis of HFpEF. Moreover, this review focuses on the adequate treatment of comorbidities and risk factors in HFpEF that should be an essential part of any HFpEF therapy. Furthermore, the management of fluid level in HFpEF patients is pointed out, as it plays an important role in symptom control. In addition, the value of LCZ696 therapy in HFpEF is discussed. Although LCZ696 had neutral effects in the large PARAGON-HF trial, it had previously been granted an extended indication by the Food and Drug Administration. Since the publication of the EMPEROR-Preserved trial, empagliflozin now represents the first drug to significantly improve the prognosis of HFpEF patients. Therefore, the role of SGLT2 inhibitors in HFpEF management is highlighted. Overall, this review aims to enhance the knowledge on the diagnostic processes and best treatments available for HFpEF patients.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N87cfd879d7e544f2a5131e420f087e2f
25 Nd5297cf34b3a43b0a8e548af46c0a4d6
26 sg:journal.1087175
27 schema:keywords Drug Administration
28 EMPEROR-Preserved trial
29 H2FPEF
30 HFA-PEFF
31 HFpEF
32 HFpEF management
33 HFpEF patients
34 HFpEF syndrome
35 HFpEF therapy
36 LCZ696
37 LCZ696 therapy
38 PARAGON-HF trial
39 SGLT2 inhibitors
40 account
41 addition
42 adequate treatment
43 administration
44 aspects
45 best treatment
46 comorbidities
47 control
48 diagnosis
49 diagnosis of HFpEF
50 diagnostic modalities
51 diagnostic process
52 discussion
53 drugs
54 effect
55 ejection fraction
56 essential part
57 extended indications
58 factors
59 failure
60 first drug
61 fluid levels
62 food
63 fraction
64 heart failure
65 heterogeneity
66 important role
67 indications
68 inhibitors
69 knowledge
70 left ventricular ejection fraction
71 levels
72 management
73 management strategies
74 modalities
75 neutral effect
76 numerous diagnostic modalities
77 ongoing discussion
78 part
79 patients
80 process
81 prognosis
82 publications
83 review
84 risk factors
85 role
86 strategies
87 symptom control
88 syndrome
89 therapy
90 treatment
91 trials
92 values
93 ventricular ejection fraction
94 schema:name Management strategies in heart failure with preserved ejection fraction
95 schema:pagination 332-339
96 schema:productId N56ae09ed955f4517a7fe5bf2c7b2c4be
97 N77aa2c2af7c648eb86a149d96e4e0ac1
98 N9935db2ffcc342be8ef03245b449b89f
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147680082
100 https://doi.org/10.1007/s00059-022-05119-5
101 schema:sdDatePublished 2022-10-01T06:50
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N518248c054af41a88f6358b714377628
104 schema:url https://doi.org/10.1007/s00059-022-05119-5
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N159b7d539a0047fba4ef6526dab62ec5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Sodium-Glucose Transporter 2 Inhibitors
110 rdf:type schema:DefinedTerm
111 N28b81c3f53ad4f148b4660b7dfc45e05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Comorbidity
113 rdf:type schema:DefinedTerm
114 N518248c054af41a88f6358b714377628 schema:name Springer Nature - SN SciGraph project
115 rdf:type schema:Organization
116 N56338cdac5c146768cb499985c284f80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N56ae09ed955f4517a7fe5bf2c7b2c4be schema:name doi
120 schema:value 10.1007/s00059-022-05119-5
121 rdf:type schema:PropertyValue
122 N77aa2c2af7c648eb86a149d96e4e0ac1 schema:name dimensions_id
123 schema:value pub.1147680082
124 rdf:type schema:PropertyValue
125 N7b39c66b9f1e4fc697e691a3f833b15e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Ventricular Function, Left
127 rdf:type schema:DefinedTerm
128 N87cfd879d7e544f2a5131e420f087e2f schema:issueNumber 4
129 rdf:type schema:PublicationIssue
130 N8e53dad978f940dcb3193a8778009944 rdf:first sg:person.01075440347.57
131 rdf:rest Ncde4574f086046799680cd4bdaf24bbd
132 N9935db2ffcc342be8ef03245b449b89f schema:name pubmed_id
133 schema:value 35524007
134 rdf:type schema:PropertyValue
135 Ncb3e480db10f4597b5de18c42466a7cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Stroke Volume
137 rdf:type schema:DefinedTerm
138 Ncde4574f086046799680cd4bdaf24bbd rdf:first sg:person.01252023603.69
139 rdf:rest rdf:nil
140 Nd5297cf34b3a43b0a8e548af46c0a4d6 schema:volumeNumber 47
141 rdf:type schema:PublicationVolume
142 Ndd5e8242d2f0444c8cc52ee2c50ced77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Heart Failure
144 rdf:type schema:DefinedTerm
145 Nf73ddae420aa49d3a933c2e6959de4c9 rdf:first sg:person.07362710151.74
146 rdf:rest N8e53dad978f940dcb3193a8778009944
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
151 schema:name Cardiorespiratory Medicine and Haematology
152 rdf:type schema:DefinedTerm
153 sg:journal.1087175 schema:issn 0340-9937
154 1615-6692
155 schema:name Herz
156 schema:publisher Springer Nature
157 rdf:type schema:Periodical
158 sg:person.01075440347.57 schema:affiliation grid-institutes:None
159 schema:familyName Abdin
160 schema:givenName Amr
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075440347.57
162 rdf:type schema:Person
163 sg:person.01252023603.69 schema:affiliation grid-institutes:None
164 schema:familyName Böhm
165 schema:givenName Michael
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252023603.69
167 rdf:type schema:Person
168 sg:person.07362710151.74 schema:affiliation grid-institutes:None
169 schema:familyName Wintrich
170 schema:givenName Jan
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07362710151.74
172 rdf:type schema:Person
173 sg:pub.10.1007/s00392-017-1170-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092151548
174 https://doi.org/10.1007/s00392-017-1170-6
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s00392-018-1210-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1100823936
177 https://doi.org/10.1007/s00392-018-1210-x
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s00392-018-1302-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105178358
180 https://doi.org/10.1007/s00392-018-1302-7
181 rdf:type schema:CreativeWork
182 sg:pub.10.1007/s00392-018-1344-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1105856283
183 https://doi.org/10.1007/s00392-018-1344-x
184 rdf:type schema:CreativeWork
185 sg:pub.10.1007/s00392-019-01411-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112260110
186 https://doi.org/10.1007/s00392-019-01411-3
187 rdf:type schema:CreativeWork
188 sg:pub.10.1007/s00392-019-01477-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1113380525
189 https://doi.org/10.1007/s00392-019-01477-z
190 rdf:type schema:CreativeWork
191 sg:pub.10.1007/s00392-020-01633-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1126009394
192 https://doi.org/10.1007/s00392-020-01633-w
193 rdf:type schema:CreativeWork
194 sg:pub.10.1007/s11897-014-0219-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006262431
195 https://doi.org/10.1007/s11897-014-0219-3
196 rdf:type schema:CreativeWork
197 sg:pub.10.1038/nrcardio.2017.65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085388588
198 https://doi.org/10.1038/nrcardio.2017.65
199 rdf:type schema:CreativeWork
200 grid-institutes:None schema:alternateName Klinik für Innere Medizin III—Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany
201 schema:name Klinik für Innere Medizin III—Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Kirrberger Str., 66421, Homburg/Saar, Germany
202 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...